Investor Presentaiton
Novo Nordisk Annual Report 2023
Cash flow statement
for the year ended 31 December
DKK million
Cash flow statement
Net profit
Adjustment of non-cash items:
Income taxes in the income statement
Introducing Novo Nordisk Strategic Aspirations
Risks
Management
Consolidated statements
Additional information.
51
Note
2023
2022
2021
DKK million
83,683
55,525
47,757
Purchase of treasury shares
Dividends paid
Proceeds from borrowings
2.6
20,991
13,537
11,323
Repayment of borrowings
Depreciation, amortisation and impairment losses
3.1, 3.2
9,413
7,362
6,025
Net cash used in financing activities
Other non-cash items
4.8
32,382
22,310
Change in working capital
4.8
(12,245)
(5,336)
13,416
(9,063)
Net cash generated from activities
Interest received
1,072
276
241
Interest paid
(491)
(272)
Income taxes paid
2.6
(25,897)
(14,515)
(261)
(14,438)
Cash and cash equivalents at the beginning of the year
Exchange gains/(losses) on cash and cash equivalents
Cash and cash equivalents at the end of the year
Net cash generated from operating activities
108,908
78,887
55,000
Purchase of intangible assets
3.1
(13,090)
(2,607)
(1,050)
Purchase of property, plant and equipment
3.2
(25,806)
(12,146)
(6,335)
Cash used for acquisition of businesses
Proceeds from other financial assets
5.3
(7,075)
(18,283)
33
Purchase of other financial assets
(271)
Purchase of marketable securities
(13,018)
Sale of marketable securities
8,260
(169)
(9,566)
6,645
(4)
(7,109)
1,172
Dividend received from associated companies
5.4
4
Net cash used in investing activities
(43,892)
(24,918)
(31,605)
Note
2023
2022
2021
4.3
(29,924)
(24,086)
(19,447)
4.2
(31,767)
(25,303)
(21,517)
4.6
11,215
22,160
4.6
(1,467)
(13,623)
(6,689)
(63,158)
(51,797)
(25,493)
1,858
2,172
(2,098)
12,653
10,719
12,226
(119)
(238)
591
4.7
14,392
12,653
10,719View entire presentation